33 completed, 16 unknown, 7 withdrawn, 3 terminated. 17 Phase 2, 10 Not applicable, 7 Phase 3, 4 Phase 1, 3 Phase 4.
Follow Coronavirus Disease 2019: new trials by email Literature Review of Coronavirus Disease 2019 trials Research Report on Coronavirus Disease 2019
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir Ibuzatrelvir co-process API film coated tablet, Ibuzatrelvir filmcoated tablet - Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19) | Phase 1 | Completed | Pfizer | 17 | 2026-04-13 | 2026-07-28 |
| LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia LIAISON NES FLU A/B, RSV, & COVID-19, LIAISON PLEX Respiratory Flex Assay - Influenza A, Influenza Type B | Not applicable | Unknown | DiaSorin Molecular LLC | 1000 | 2024-05-06 | 2024-04-30 |
| A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza. COVID-19 Vaccine - COVID-19, Coronavirus Disease 2019 | Withdrawn | Pfizer | 2024-01-17 | 2024-03-01 | ||
| LIAISON NES Influenza (FLU) A/B & Coronavirus Disease 2019 (COVID-19) Clinical Agreement in Australia LIAISON NES FLU A/B & COVID-19 - Influenza A, Influenza Type B | Not applicable | Completed | DiaSorin Molecular LLC | 233 | 2023-06-19 | 2024-04-30 |
| Evaluation of KGR Prescriptions in Suppressing COVID-19 Infection. Kang Guan Recipe (Treat), Kang Guan Recipe (Placebo) - Coronavirus Disease 2019, Severe Acute Respiratory Syndrome Coronavirus 2 Infection | Phase 1 | Completed | Sheng-Teng Huang | 26 | 2023-02-09 | 2024-03-06 |
| Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1) Famotidine, Celecoxib, Placebo - 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection | Phase 2 | Withdrawn | Leidos Life Sciences | 2023-02-07 | 2023-10-10 | |
| Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III Chlorpheniramine Maleate 0.4% Nasal Spray, Placebo - COVID-19, Symptoms and Signs | Phase 2 / Phase 3 | Completed | Dr. Ferrer BioPharma | 157 | 2022-07-27 | 2023-06-02 |
| SARS-CoV-2 Nucleic Acid Detection Kit Clinical Performance Study Left-overs - COVID-19, Coronavirus Disease 2019 | Completed | TransGen Biotech Co., LTD | 607 | 2022-07-05 | 2023-05-18 | |
| A Phase Ia Clinical Study to Evaluate the Safety, Tolerability, PK and Immunogenicity of YBSW015 in Healthy Subjects YBSW015 injection - Coronavirus Disease 2019 | Early Phase 1 | Unknown | Yabao Pharmaceutical Group | 40 | 2022-07-01 | 2022-05-11 |
| Comparison of General Characteristics of Patients Diagnosed COVID-19 (Coronavirus )Positive Followed In Service Coronavirus Disease 2019, Vaccinia | Unknown | Saglik Bilimleri Universitesi | 45 | 2022-05-05 | 2022-05-06 | |
| Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation Diagnostic Test: Diagnostic Software as Medical Device - 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection | Completed | AudibleHealth AI, Inc. | 514 | 2022-05-04 | 2022-07-20 | |
| Huashi Baidu Granule in the Treatment of Pediatric Patients With Mild Coronavirus Disease 2019 Huashi Baidu granule, compound pholcodine oral solution - Coronavirus Disease 2019 | Not applicable | Completed | Shanghai Children's Medical Center | 108 | 2022-05-01 | 2022-08-16 |
| SOLIDARITY Finland Plus Long-COVID Imatinib, Infliximab - Covid19, Coronavirus Disease 2019 | Phase 4 | Unknown | Clinical Urology and Epidemiology Working Group | 400 | 2022-02-06 | 2022-05-03 |
| A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza COVID-19 Vaccine - COVID-19, Coronavirus Disease 2019 | Active not recruiting | Pfizer | 999 | 2022-01-31 | 2026-03-31 | |
| Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients Famotidine, Celecoxib, Placebo - 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection | Phase 2 | Terminated | Leidos Life Sciences | 4 | 2021-12-29 | 2024-07-09 |
| LEAP-CT for Treatment of COVID-19 Patients (Master Protocol) Famotidine, Celecoxib, Placebo - 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection | Phase 2 | Completed | Leidos Life Sciences | 4 | 2021-12-29 | 2025-12-16 |
| Prone Positioning in COVID-19 Patients Oxygenation - Coronavirus Disease 2019, ARDS | Not applicable | Unknown | Tepecik Training and Research Hospital | 50 | 2021-12-25 | 2022-02-01 |
| Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-I Chlorpheniramine Maleate 1% Nasal Spray, Placebo - COVID-19, Symptoms and Signs | Phase 2 / Phase 3 | Completed | Dr. Ferrer BioPharma | 101 | 2021-12-07 | 2023-03-23 |
| Masitinib in Patients With Symptomatic Mild to Moderate COVID-19 Masitinib Mesylate, Placebo - Covid19, SARS-CoV2 Infection | Phase 2 | Unknown | AB Science | 78 | 2021-11-23 | 2023-02-06 |
| LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia LB1148, Placebo - COVID-19, Coronavirus Disease 2019 | Phase 2 | Withdrawn | Leading BioSciences, Inc | 2021-10-31 | 2022-05-13 |
Showing 20 of 62. Sign in to see all of them.
COVID-19 (62) · Coronavirus Infections (6) · Signs and Symptoms (3) · Influenza, Human (2) · Lymphopenia (2) · Psychological Well-Being (2) · Respiratory Distress Syndrome (2) · Respiratory Tract Diseases (2) · Acute Lung Injury (1) · Adenoviridae Infections (1) · Alopecia (1) · Anosmia (1) · Candidiasis, Oral (1) · Chilblains (1) · Coronaviridae Infections (1)
Nidovirales Infections (62) · Coronaviridae Infections (61) · Infections (61) · Lung Diseases (61) · Pneumonia (61) · Pneumonia, Viral (61) · RNA Virus Infections (61) · Respiratory Tract Infections (61) · Virus Diseases (61) · Respiratory Tract Diseases (60) · Coronavirus Infections (56) · Pathological Conditions, Signs and Symptoms (10) · Cardiovascular Diseases (4) · Nervous System Diseases (4) · Pathologic Processes (4)
Celecoxib (3) · Famotidine (3) · Population Groups (3) · leronlimab (3) · COVID-19 Vaccines (2) · Chlorpheniramine (2) · Nasal Sprays (2) · Observation (2) · Standard of Care (2) · masitinib (2) · 2019-nCoV Vaccine mRNA-1273 (1) · Angiotensin Receptor Antagonists (1) · Autoimmunity (1) · BNT162 Vaccine (1) · ChAdOx1 nCoV-19 (1)
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (4) · CytoDyn, Inc. (3) · Leidos Life Sciences (3) · Pfizer (3) · AB Science (2) · Azienda Ospedaliera Universitaria Integrata Verona (2) · DiaSorin Molecular LLC (2) · Dr. Ferrer BioPharma (2) · Second Affiliated Hospital of Xi'an Jiaotong University (2) · AO GENERIUM (1) · Assiut University (1) · AudibleHealth AI, Inc. (1) · Clinical Urology and Epidemiology Working Group (1) · Damanhour University (1) · EMD Serono Research & Development Institute, Inc. (1)
United States (16) · China (9) · France (4) · Australia (3) · Belgium (3) · Philippines (3) · Russia (3) · Spain (3) · Argentina (2) · Brazil (2) · Egypt (2) · Honduras (2) · Italy (2) · Pakistan (2) · Turkey (Türkiye) (2)
Tao Huang (3) · Brian A Roberts, MS, PMP (2) · Janet Farhang, PhD (2) · Rabia Ghafoor, MBBS, FCPS, SCE-Derm(MRCP-UK) (2) · Shouping Gong, MD, PhD (2) · Syeda Mahanum Ali, MBBS, Postgraduate Trainee (2) · Adrian I Espiritu, MD (1) · Ahmed M El-Menshawy, Lect. (1) · Alaa M Mohamed, Lect. (1) · Aliaa Abd-Raboh Mohamed, Professor (1) · Alicia Mistchenko, Phd (1) · Andrea Gamarnick, Phd (1) · Angela Ritter, MD (1)
PMID 36048877, PMID 33213035, PMID 33257488, PMID 33367731, PMID 33647535, PMID 34448930, PMID 34454580, PMID 34467402, PMID 34868084, PMID 35390178, PMID 35452519, PMID 35477480, PMID 36130741, PMID 36200701, PMID 36384746, PMID 36719885, PMID 37117213, PMID 37222316, PMID 37347370, PMID 37654668, PMID 37679771, PMID 37873555, PMID 38171619, PMID 39019657, PMID 39353749, PMID 39436613, PMID 39684943, PMID 41557260, PMID 42426637
2025 (1), R01HL159055 (1)